A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 1114-1122

  Mir, Youssef ^a   Elrington, Stefan A ^a   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug delivery; EGFR; Liposome; Ovarian cancer; Targeted photodynamic therapy

Indexed keywords

BENZOPORPHYRIN-DERIVATIVE MONOACID; EGFR; EPIDERMAL GROWTH FACTOR RECEPTORS; EPIDERMAL GROWTH FACTORS; FLUORESCENCE QUANTUM YIELD; OVARIAN CANCER CELLS; OVARIAN CANCERS; SPATIAL LOCALIZATION;

ADSORPTION; ANTIBODIES; CELL DEATH; DRUG DELIVERY; LIPOSOMES; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS;

DISEASES;

CETUXIMAB; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOSOME; PHOTOIMMUNO CONJUGATE ASSOCIATING LIPOSOME; PREFORMED PLAIN LIPOSOME; UNCLASSIFIED DRUG; VERTEPORFIN;

ADSORPTION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG RELEASE; DRUG STABILITY; FLUORESCENCE ANALYSIS; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOLECULE; OPTICS; OVARY CANCER; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; QUANTUM YIELD; SIGNAL TRANSDUCTION; TARGETED PHOTODYNAMIC THERAPY;

DRUG DELIVERY; EGFR; LIPOSOME; OVARIAN CANCER; TARGETED PHOTODYNAMIC THERAPY;

ABSORPTION; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL SURVIVAL; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENCE; HUMANS; IMMUNOBLOTTING; IMMUNOTHERAPY; LIPOSOMES; MOLECULAR TARGETED THERAPY; NANOPARTICLES; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; PORPHYRINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884291697     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.02.005     Document Type: Article

References (47)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428.
3. del Carmen M.G., Rizvi I., Chang Y., Moor A.C., Oliva E., Sherwood M., et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 2005, 97:1516-1524.
4. Abu-Yousif A.O., Moor A.C., Zheng X., Savellano M.D., Yu W., Selbo P.K., et al. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett 2012, 321:120-127.
5. Juliano R.L. The future of nanomedicine: promises and limitations. Science and Public Policy 2012, 39:99-104.
6. Gao J., Feng S.S., Guo Y. Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) 2010, 5:1141-1145.
7. Paszko E., Senge M.O. Immunoliposomes. Curr Med Chem 2012, 19:5239-5277.
8. Bugaj A.M. Targeted photodynamic therapy - a promising strategy of tumor treatment. Photochem Photobiol Sci 2011, 10:1097-1109.
9. Duska L.R., Hamblin M.R., Miller J.L., Hasan T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J Natl Cancer Inst 1999, 91:1557-1563.
10. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5:909-916.
11. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 3:2703-2707.
12. Bull Phelps S.L., Schorge J.O., Peyton M.J., Shigematsu H., Xiang L.L., Miller D.S., et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 2008, 109:411-417.
13. Psyrri A., Kassar M., Yu Z., Bamias A., Weinberger P.M., Markakis S., et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005, 11:8637-8643.
14. Fan Z., Masui H., Altas I., Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993, 53:4322-4328.
15. Prewett M., Rockwell P., Rockwell R.F., Giorgio N.A., Mendelsohn J., Scher H.I., et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996, 19:419-427.
16. Guyon L., Ascencio M., Collinet P., Mordon S. Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer. Photodiagnosis Photodyn Ther 2012, 9:16-31.
17. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
18. Hahn S.M., Fraker D.L., Mick R., Metz J., Busch T.M., Smith D., et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006, 12:2517-2525.
19. Sadzuka Y., Tokutomi K., Iwasaki F., Sugiyama I., Hirano T., Konno H., et al. The phototoxicity of photofrin was enhanced by PEGylated liposome in vitro. Cancer Lett 2006, 241:42-48.
20. Sibrian-Vazquez M., Jensen T.J., Hammer R.P., Vicente M.G. Peptide-mediated cell transport of water soluble porphyrin conjugates. J Med Chem 2006, 49:1364-1372.
21. Portnoy E., Lecht S., Lazarovici P., Danino D., Magdassi S. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine : nanotechnology, biology, and medicine 2011, 7:480-488.
22. Cengel K.A., Hahn S.M., Glatstein E. C225 and PDT combination therapy for ovarian cancer: the play's the thing. J Natl Cancer Inst 2005, 97:1488-1489.
23. Aveline B., Hasan T., Redmond R.W. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol 1994, 59:328-335.
24. Goding J.W. Conjugation of antibodies with fluorochromes: modifications to the standard methods. J Immunol Methods 1976, 13:215-226.
25. Demas J.N., Crosby G.A. Measurement of photoluminescence quantum yields. Review. J Phys Chem 1971, 75:991-1024.
26. Xia W., Wei Y., Du Y., Liu J., Chang B., Yu Y.L., et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009, 48:610-617.
27. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995, 16:141-155.
28. Dos Santos N., Allen C., Doppen A.M., Anantha M., Cox K.A., Gallagher R.C., et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 2007, 1768:1367-1377.
29. Senior J., Waters J.A., Gregoriadis G. Antibody-coatedliposomes: the role of non-specific antibodyadsorption. FEBS Lett 1986, 196:54-58.
30. Aveline B.M., Hasan T., Redmond R.W. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). J Photochem Photobiol B 1995, 30:161-169.
31. Ricchelli F., Gobbo S., Moreno G., Salet C., Brancaleon L., Mazzini A. Photophysical properties of porphyrin planar aggregates in liposomes. European journal of biochemistry / FEBS 1998, 253:760-765.
32. Margalit R., Cohen S. Studies of hematoporphyrin and hematoporphyrin derivative equilibria in heterogeneous systems. Porphyrin-liposome binding and porphyrin aqueous dimerization. Biochim Biophys Acta 1983, 736:163-170.
33. Beduneau A., Saulnier P., Hindre F., Clavreul A., Leroux J.C., Benoit J.P. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 2007, 28:4978-4990.
34. Ricchelli F., Stevanin D., Jori G. Porphyrin-liposome interactions: influence of the physico-chemical properties of the phospholipid bilayer. Photochem Photobiol 1988, 48:13-18.
35. Lavi A., Weitman H., Holmes R.T., Smith K.M., Ehrenberg B. The depth of porphyrin in a membrane and the membrane's physical properties affect the photosensitizing efficiency. Biophys J 2002, 82:2101-2110.
36. Vandenbranden M., Decoen J.L., Jeener R., Kanarek L., Ruyschaert J.M. Interactions of gamma-immunoglobulins with lipid monolayers or bilayers and liposomes - existence of 2 conformations of gamma-immunoglobulins of different hydrophobicities. Mol Immunol 1981, 18:621-631.
37. Blomberg E., Claesson P.M., Froberg J.C. Surfaces coated with protein layers: a surface force and ESCA study. Biomaterials 1998, 19:371-386.
38. Wiedmer S.K., Jussila M., Hakala R.M., Pystynen K.H., Riekkola M.L. Piperazine-based buffers for liposome coating of capillaries for electrophoresis. Electrophoresis 2005, 26:1920-1927.
39. Bo T., Wiedmer S.K., Riekkola M.L. Phospholipid-lysozyme coating for chiral separation in capillary electrophoresis. Electrophoresis 2004, 25:1784-1791.
40. Seiden M.V., Burris H.A., Matulonis U., Hall J.B., Armstrong D.K., Speyer J., et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007, 104:727-731.
41. Fanuel-Barret D., Patrice T., Foultier M.T., Vonarx-Coinsmann V., Robillard N., Lajat Y. Influence of epidermal growth factor on photodynamic therapy of glioblastoma cells in vitro. Res Exp Med (Berl) 1997, 197:219-233.
42. Tong Z., Singh G., Rainbow A.J. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Cancer Res 2002, 62:5528-5535.
43. Ahmad N., Kalka K., Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy. Oncogene 2001, 20:2314-2317.
44. Wong T.W., Tracy E., Oseroff A.R., Baumann H. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003, 63:3812-3818.
45. Edmonds C, Hagan S, Gallagher-Colombo SM, Busch TM, Cengel KA. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer Biol Ther 2012;13.
46. Master A.M., Qi Y., Oleinick N.L., Gupta A.S. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine : nanotechnology, biology, and medicine 2012, 8:655-664.
47. Yip W.L., Weyergang A., Berg K., Tonnesen H.H., Selbo P.K. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007, 4:241-251.